Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opexa Goes Into Hold Mode, Awaiting Secondary Progressive MS Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.

Advertisement

Related Content

Back In The Saddle: Texas Biotech Opexa Re-Enters The Clinic With MS Immunotherapy
Opexa Pins Hope On Failed MS Vaccine’s Relapse Rate

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register